Sinusitis Disease Affecting 31M Americans

[Guest guest]

Breaking News

Email article to a colleague Printer friendly version

Accentia Biopharmaceuticals, Inc. Launches CRSFungal Profile:

The First Diagnostic Test Available for the Confirmation of Chronic

http://www.genengnews.com/news/bnitem.aspx?

name=1115256XSL_NEWSML_TO_NEWSML_WEB.xml

Sinusitis Disease Affecting 31M Americans

11/29/2005 9:27:00 AM EST

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today the

commercial introduction of a patented, non-invasive test, CRSFungal

Profile, by its specialty pharmaceuticals division, TEAMM

Pharmaceuticals, to assist in the diagnosis of Chronic Sinusitis

(CS) otherwise known as Chronic Rhinosinusitis (CRS). In partnership

with the licensee for this patented technology, IMMCO Diagnostics

Inc. (IMMCO) of Buffalo, NY, Accentia Biopharmaceuticals is making

CRSFungal Profile available to ear, nose and throat (ENT)

specialists and allergists nationwide.

CS is one of the most common chronic diseases suffered by Americans

today, affecting an estimated 31 million patients in the US. CS is a

chronic inflammatory disease of the nasal and sinus mucosa that

persists for greater than three months. Long-term consequences

include the formation of inflammatory polyps in the nose. The

inflammation of CS results in symptoms that include nasal

congestion, mouth breathing, nasal discharge, and post-nasal drip.

This chronic non-infectious inflammation predisposes patients to

acute exacerbations of their sinusitis due to bacterial

superinfection, which requires oral antibiotic therapy. Many

patients with severe disease resort to sinus surgery in an effort to

reduce nasal obstruction and improve sinus drainage.

Historically, the diagnosis of CS has been made based on a doctor's

subjective assessment of a combination of the patients' symptoms,

nasal endoscopy, and CT scan of the sinuses. There has been no

confirmatory diagnostic test for the disease.

Published studies by researchers at the Mayo Clinic in Rochester,

Minnesota have provided substantial evidence that the underlying

cause for CS is the presence of fungi, in the mucus layer of the

nasal and sinus cavities. While fungi are present in the majority of

the population, it is an inflammatory response in susceptible

patients that causes CS. This research has led to a better

understanding of the condition and it has led to the development of

new treatment strategies targeting the fungal etiology.

CRSFungal Profile enables physicians to test for the specific

protein marker, eosinophil Major Basic Protein (eMBP), as well as

one of the fungi that causes CS. The test uses a small sample of

mucus from the patient's nasal cavities. The mucus sample is sent by

the physician to IMMCO where it is analyzed by immunoassay.

Typically, results are made available to the physician within 72

hours.

" Chronic sinusitis is extremely debilitating to the millions of

sufferers worldwide. The improvements in diagnostic testing will

make it easier for the practitioner to appropriately treat these

patients, " said Dr. Sherris, Professor and Chairman,

Department of Otolaryngology, University of Buffalo. " In clinical

studies, patients with chronic sinusitis were positive for the eMBP

protein in their mucus, but it was not detected in patients with

allergic rhinitis or in normal patients. "

" We are excited to partner with IMMCO on this groundbreaking tool

for diagnosing CS. Existing interventions have been largely limited

to the use of inhaled or oral corticosteroids, decongestants, anti-

histamines, and sinus surgery but we believe that these

interventions do not address the underlying cause of the

inflammation. This is the only test on the market that physicians

can use to assist in the diagnosis of CS based on the underlying

etiology, " said Cantrell, Executive Vice President Sales and

Marketing of specialty pharmaceuticals at Accentia.

Accentia and IMMCO have toll free numbers for physicians seeking

more information or to obtain the CRSFungal Profile sample

collection kit. The toll free numbers are: Accentia 866-481-9020 or

IMMCO 800-537-8378.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company

focused on the development and commercialization of late-stage

clinical products in the therapeutic areas of respiratory disease

and oncology. The Company's SinuNase product is a novel

application and formulation of a known anti-fungal being developed

under an IND to treat chronic sinusitis (rhinosinusitis). SinuNase

was originally developed by and licensed from the Mayo Foundation

for Medical Education and Research. BIOVAXID is a patient-

specific anti-cancer vaccine intended for the treatment of

follicular non-Hodgkins' lymphoma. BIOVAXID is being developed by

our subsidiary Biovest International, Inc. (OTCBB:BVTI) and it is

currently in a pivotal Phase 3 clinical trial started by the

National Cancer Institute. In addition, Accentia has a growing

specialty pharmaceutical business with a portfolio of currently

marketed products plus a pipeline of additional products under

development by third parties. For further information, please visit

our web site: http://www.accentia.net.

About IMMCO Diagnostics, Inc.

Founded in 1971, IMMCO Diagnostics, Inc. (IMMCO) of Buffalo, New

York is a global leader in the field of autoimmune diagnostics

services and medical device manufacturing and distribution. IMMCO

has a longstanding commitment to R & D and technological advancement,

offering services and products which utilize cutting edge

methodologies to diagnose a wide range of diseases. A number of

proprietary technologies will be introduced in 2005-2006 to expand

the frontiers of autoimmunity and further differentiate IMMCO from

its global competitors.

Forward-Looking Statements

Statements in this release that are not strictly historical in

nature constitute " forward-looking statements. " Such statements

include, but are not limited to, statements about CRSFungal Profile

and any other statements relating to Accentia's products, product

candidates, and product development programs. Such statements may

include, without limitation, statements with respect to the

Company's plans, objectives, expectations and intentions and other

statements identified by words such

as " may " , " could " , " would " , " should " , " believes " , " expects " , " anticip

ates " , " estimates " , " intends " , " plans " or similar expressions. Such

forward-looking statements involve known and unknown risks,

uncertainties, and other factors that may cause Accentia's actual

results to be materially different from historical results or from

any results expressed or implied by such forward-looking statements.

These factors include, but are not limited to, risks and

uncertainties related to the progress, timing, cost, and results of

Accentia's clinical trials and product development programs;

difficulties or delays in obtaining regulatory approval for product

candidates; competition from other pharmaceutical or biotechnology

companies; and the additional risks discussed in Accentia's filings

with the Securities and Exchange Commission. All forward looking

statements are qualified in their entirety by this cautionary

statement, and Accentia undertakes no obligation to revise or update

this news release to reflect events or circumstances after the date

hereof.

CONTACT:

Accentia Biopharmaceuticals, Inc., Tampa Sherran Brewer, 866-481-9020